https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

KRAS-Targeted Vaccine Shows Durable Immune Responses, Survival Benefits in Pancreatic Colorectal Cancers

KRAS-Targeted Vaccine Shows Durable Immune Responses, Survival Benefits in Pancreatic Colorectal Cancers

Elicio Therapeutics’ ELI-002 2P cancer vaccine shows promising survival benefits in pancreatic and colorectal cancer patients, enhancing immune responses.

administrator

Related Articles